Headlines about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intec Pharma earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.8744322503353 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
NTEC has been the topic of several recent analyst reports. Oppenheimer set a $15.00 target price on Intec Pharma and gave the company a “buy” rating in a report on Monday. Zacks Investment Research raised Intec Pharma from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Wednesday, November 22nd. Maxim Group set a $8.00 target price on Intec Pharma and gave the company a “buy” rating in a report on Friday, November 17th. CIBC reissued an “outperform” rating and issued a $15.00 target price (up previously from $10.00) on shares of Intec Pharma in a report on Thursday, September 21st. Finally, ValuEngine lowered Intec Pharma from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $11.00.
Shares of Intec Pharma (NTEC) traded down $0.05 during mid-day trading on Tuesday, hitting $4.90. The company’s stock had a trading volume of 92,000 shares, compared to its average volume of 49,256. Intec Pharma has a 12 month low of $4.20 and a 12 month high of $9.80.
TRADEMARK VIOLATION WARNING: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://sportsperspectives.com/2017/12/19/intec-pharma-ntec-earning-somewhat-positive-media-coverage-analysis-finds.html.
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.